Genmab A/S

NASDAQ:GMAB

Biotechnology

Healthcare
$50.97 -0.47%

-$0.12 today

Market cap
$31.43B
Beta
0.68
P/E (TTM)
18.7
EPS (TTM)
$13.36
52W Low $20.23High $35.43

Volume 2.96M

Average 1.85M

GMAB Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Genmab A/SNASDAQ: GMAB

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation grows 12.1% year over year

Q2 FY2026 stock-based compensation of $37M rose 12.1% year over year.

Context

  • Stock-based compensation amounted to 0.0% of revenue in FY2025, down 3.3 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$37M— QoQ
Last fiscal yearDec 2025
$0-100.0% YoY
LTMJun 2026
$71M— YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.1%——
1 year-100.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

Mixed currencies · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Stock-Based Compensation vs competitors

How GMAB compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Stock-based compensation amounts to 1.7% of revenue for GMAB, versus a peer median of 4.6%.
GMAB Competitors
Stock-Based Compensation for GMAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
INCYIncyte CorporationLTM Jun 2026$187.88M USD-31.7%+9.8%3.2%
EXELExelixis, Inc.LTM Jul 2026$112.6M USD+1.1%+1.6%4.6%
GMABGenmab A/SLTM Jun 2026$71M USD——1.7%
RCUSArcus Biosciences, Inc.LTM Jun 2026$63M USD-6.0%-2.6%53.8%
IOVAIovance Biotherapeutics, Inc.LTM Sep 2026$46.65M USD-42.2%-9.8%12.3%
ADCTADC Therapeutics S.A.LTM Mar 2026$12.63M USD+26.4%-48.5%16.0%
MGNXMacroGenics, Inc.LTM Mar 2026$12.55M USD-55.6%-11.3%8.0%
ALXOALX Oncology Holdings Inc.LTM Mar 2026$9.87M USD-60.9%-19.2%—
LEGNLegend Biotech CorporationLTM Sep 2026$7.7M USD-87.8%—0.6%
BNTXBioNTech SELTM Jun 2026€0 EUR——0.0%
CGENCompugen Ltd.LTM Dec 2025$0 USD——0.0%
Peer median (excluding GMAB) —-37.0%-9.8%4.6%

Competitors are the stored peer set for GMAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

Mixed currencies
Metric
FY2021
Dec 2021 · DKK
FY2022
Dec 2022 · DKK
FY2023
Dec 2023 · DKK
FY2024
Dec 2024 · DKK
FY2025
Dec 2025 · USD
Net Income3.98B7.04B5.64B7.84B963.76M
Depreciation & Amortization248.99M362M293.62M413M71.06M
Deferred Income Tax(546M)0122M00
Stock-Based Compensation310M439M586M721M0
Change in Working Capital(770M)(1.93B)1.36B(1.6B)225.18M
Accounts Receivables(1.07B)(2.12B)797M(1.59B)(166.13M)
Inventory00(57M)(5M)(9.01M)
Accounts Payables304M283M622M0400.32M
Other Working Capital0(90M)000
Other Non-Cash Items(997.99M)(1.99B)(620.62M)388M(73.06M)
Operating Cash Flow2.23B3.91B7.38B7.77B1.19B
Capital Expenditures(252M)(317M)(376M)(187M)(37.03M)
Acquisitions (Net)709M2.44B0(12.25B)(7.22B)
Purchases of Investments(15.62B)(9.7B)(10.91B)(8.64B)(995.78M)
Sales of Investments14.91B7.25B10B11.28B2.62B
Other Investing Activities(709M)(2.44B)(10M)(117M)0
Investing Cash Flow(961M)(2.76B)(1.28B)(9.91B)(5.65B)
Debt Repayment(58M)(73M)(91M)(60M)5.23B
Common Stock Issued000023.02M
Common Stock Repurchased(447M)(908M)(564M)(3.99B)(430.34M)
Dividends Paid00000
Other Financing Activities85M192M49M129M(31.02M)
Financing Cash Flow(420M)(789M)(606M)(3.92B)4.79B
Effect of Forex Changes850M574M(518M)1.05B13.06M
Net Change in Cash1.7B936M4.97B(5.01B)345.33M
Free Cash Flow1.98B3.6B7B7.58B1.15B

Genmab A/S

NASDAQ:GMAB

Intrinsic Alpha fair value

Locked

Current Price

$50.97

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.